Blair William & Co. IL Boosts Position in Insulet Co. (PODD)
Blair William & Co. IL increased its position in Insulet Co. (NASDAQ:PODD) by 4.4% in the third quarter, HoldingsChannel reports. The firm owned 16,340 shares of the medical instruments supplier’s stock after purchasing an additional 692 shares during the quarter. Blair William & Co. IL’s holdings in Insulet were worth $1,731,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Chicago Equity Partners LLC acquired a new position in Insulet in the second quarter worth about $375,000. Oppenheimer Asset Management Inc. acquired a new position in Insulet in the second quarter worth about $300,000. Paloma Partners Management Co boosted its stake in Insulet by 2,104.4% in the second quarter. Paloma Partners Management Co now owns 168,699 shares of the medical instruments supplier’s stock valued at $14,458,000 after acquiring an additional 161,046 shares during the period. OppenheimerFunds Inc. boosted its stake in Insulet by 26.6% in the second quarter. OppenheimerFunds Inc. now owns 791,702 shares of the medical instruments supplier’s stock valued at $67,848,000 after acquiring an additional 166,585 shares during the period. Finally, State of Wisconsin Investment Board boosted its stake in Insulet by 78.7% in the second quarter. State of Wisconsin Investment Board now owns 71,482 shares of the medical instruments supplier’s stock valued at $6,126,000 after acquiring an additional 31,482 shares during the period.
Shares of NASDAQ PODD opened at $83.96 on Friday. The company has a debt-to-equity ratio of 2.95, a current ratio of 4.58 and a quick ratio of 3.99. The company has a market cap of $4.88 billion, a PE ratio of -182.52 and a beta of 1.70. Insulet Co. has a 12-month low of $67.43 and a 12-month high of $108.90.
A number of brokerages have commented on PODD. Zacks Investment Research downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Friday, August 17th. BidaskClub downgraded Insulet from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 25th. Oppenheimer set a $100.00 target price on Insulet and gave the company a “hold” rating in a research note on Friday, November 2nd. Morgan Stanley lifted their target price on Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. Finally, Leerink Swann restated an “outperform” rating and issued a $130.00 target price on shares of Insulet in a research note on Tuesday, September 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $101.44.
In other news, SVP David Colleran sold 6,113 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $80.41, for a total transaction of $491,546.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Aiman Abdel-Malek sold 602 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $88.58, for a total value of $53,325.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,053 shares of company stock valued at $756,844. Insiders own 3.60% of the company’s stock.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Further Reading: Diversification For Individual Investors
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.